trientine has been researched along with Adverse Drug Event in 3 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We retrospectively analyzed 235 Wilson disease patients." | 1.43 | Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy. ( Ferenci, P; Gohdes, A; Gotthardt, DN; Pfeiffenberger, J; Schäfer, M; Seessle, J; Stremmel, W; Weiss, KH, 2016) |
| " Chelator-based treatment regimens were analyzed for their effect on neurologic and hepatic symptoms and for adverse events that led to discontinuation of therapy (Kaplan-Meier estimation; data were collected for a mean of 13." | 1.39 | Efficacy and safety of oral chelators in treatment of patients with Wilson disease. ( Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Weiss, KH | 2 |
| Thurik, F | 1 |
| Gotthardt, DN | 2 |
| Schäfer, M | 2 |
| Teufel, U | 1 |
| Wiegand, F | 1 |
| Merle, U | 1 |
| Ferenci-Foerster, D | 1 |
| Maieron, A | 1 |
| Stauber, R | 1 |
| Zoller, H | 1 |
| Schmidt, HH | 1 |
| Reuner, U | 1 |
| Hefter, H | 1 |
| Trocello, JM | 1 |
| Houwen, RH | 1 |
| Ferenci, P | 2 |
| Stremmel, W | 2 |
| Seessle, J | 1 |
| Gohdes, A | 1 |
| Pfeiffenberger, J | 1 |
3 other studies available for trientine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Topics: Adolescent; Adult; Austria; Chelating Agents; Child; Child, Preschool; Cohort Studies; Drug-Related | 2013 |
Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Chelating Agents; Child; Cross-Sect | 2016 |